Thursday, April 29, 2010

First approval for vaccine from cancer - Dungreon's Provenge

The FDA approved Dendreon's immunotherapy Provenge for the treatment of certain men with advanced prostate cancer, marking the first approval of a vaccine to treat cancer. Karen Midthun, acting director of the FDA’s Center for Biologics Evaluation and Research said the autologous cellular immunotherapy "provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available.”


No comments:

Post a Comment